
Exagen (($XGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Exagen’s earnings call carried a strongly positive tone, supported by record third-quarter revenue,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| XGN | Exagen | 3.77 | -4.70 | -55.49% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.77 | -55.49% |

Exagen (($XGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Exagen’s earnings call carried a strongly positive tone, supported by record third-quarter revenue,

Roth Capital lowered the firm’s price target on Exagen (XGN) to $9 from $11 and keeps a Buy rating on the shares. Excluding prior-period collections, the company’s Q3 revenues were

Canaccord lowered the firm’s price target on Exagen (XGN) to $9 from $11 and keeps a Buy rating on the shares. The firm updated its model following Q3 results and

Canaccord lowered the firm’s price target on Exagen (XGN) to $9 from $11 and keeps a Buy rating on the shares, citing reduced near- and long-term revenue estimates after the

Reports Q3 revenue $18.42M, consensus $18.34M. “Our third quarter extends what is fast becoming a record year for Exagen (XGN), and our ability to execute against our vision is increasingly

The company said, “The company reiterated full-year 2026 revenue guidance of $72 million to $75 million.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

09:34 EST Exagen (XGN) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

Exagen (XGN) is scheduled to report 3rd quarter earnings on 11/10/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Exagen to post earnings of -$0.18 per share.

Canaccord analyst Kyle Mikson raised the firm’s price target on Exagen (XGN) to $11 from $9 and keeps a Buy rating on the shares. The firm updated its model ahead

TD Cowen analyst Dan Brennan raised the firm’s price target on Exagen (XGN) to $11 from $10 and keeps a Buy rating on the shares. The firm adjusted targets in
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 16, 2027TBA | $105.37M | $-0.19 | $18.08M | -0.54 | -5.43 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.